Innovative cell-based therapies are being developed to repair, replace, or regenerate absent, injured, or diseased tissues and organs. T ese investigational therapies of er promise for the treatment of many serious medical conditions, which is illustrated by the variety of indications currently under investigation in clinical trials (see www. clinicaltrials.gov). In the United States, cell-based regenerative medicine (RM) products are regulated by the U.S. Food and Drug Administration (FDA) through the Center for Biologics Evaluation and Research (CBER). Before initiation of a clinical trial for a specif c RM product, it is the responsibility of FDA's CBER review staf to establish whether clinical trial participants would be exposed to substantial and unreasonable risks.
From 2007 to 2011, CBER received ~115 original submissions from academic and commercial sponsors requesting permission to begin clinical investigations of cell-based RM products for many dif erent indications, including cardiovascular diseases, diabetes, neurodegenerative disorders, wound healing, and others. For this analysis, the number of submissions excludes products for oncology indications or those manufactured by use of genetic engineering. T e identity and tissue sources of these cell-based RM products span a wide spectrum (Fig. 1) , ranging from functionally specialized and lineage-restricted cells to products derived from unspecialized pluripotent embryonic stem (ES) cells.
PROMISE AND RISK
T e promise of many cell-based RM products is based on their inherent biological properties-high rates of proliferation, migratory (traf cking) ability, plasticity, and capacity for self-renewal. However, these same properties also pose particular challenges during product development. T e potential for tumor formation is a major safety concern for products derived from undif erentiated or incompletely dif erentiated cells or from cells that have undergone extensive ex vivo manipulation. Indeed, the formation of teratomas af er injection of undif erentiated ES cells into immunodef cient mice is a distinguishing feature, and the potential for malignant transformation and inappropriate dif erentiation of cells undergoing prolonged or rapid expansion is well documented (1) (2) (3) . T e p otential for tumor formation should also be considered in the context of the anatomical location of any found tumor or undesired tissue because increased damage to normal host tissue may result if cells proliferate in an anatomically constrained or sensitive area, such as the spinal column or retinal space (4).
FDA and other regulatory agencies recognize the inherent risk of tumor formation for many cell-based RM products (5) (6) (7) . T e importance of appropriate preclinical testing to identify, characterize, and minimize this risk has also been discussed by the FDA Cellular, Tissue, and Gene T erapies Advisory Committee (8, 9) . During FDA/CBER regulatory review, the potential for tumor formation is considered for all cell-based RM products (Fig.  1) . Many of the principles described in this article determined the methods of evaluation and mitigation strategies that were appropriate for each product.
Extra caution is warranted for ES cellderived products to ensure that the proportion of residual undif erentiated cells in the f nal product is as low as technically feasible. Other less well understood risk factors, such as chromosomal instability, may be identif ed and minimized through appropriate preclinical testing (and subsequent changes to product manufacturing processes). An appropriate program could include in vitro testing (such as chromosomal analysis), in vivo evaluation of proliferation and tumor formation af er product administration at the clinically relevant anatomical location, additional product characterization (such as whole-genome microarray analysis), or changes in product manufacturing (such as antibody-mediated cell sorting for the targeted depletion of undesired phenotypes).
A set of general principles can guide preclinical testing strategies for evaluating the tumorigenicity of regenerative medicine products. The cellular components of these products spanned a wide spectrum of (A) cell types and (B) tissue sources; ~70% of submissions were for new products and 30% were for new indications for previously evaluated (crossreferenced) products. Assessment of tumorigenicity risk was performed by direct testing of the product (in vitro or in vivo studies) (43%) or through consideration of product attributes, the scientifi c literature, and/or previous clinical experience (57%). FOCUS TUMORIGENICITY TESTING CHALLENGES Designing appropriate preclinical testing programs to evaluate the tumorigenic potential of a cell-based RM product is challenging for several reasons: (i) the heterogeneity and biological complexity of cell-based RM products; (ii) the lack of a complete understanding of cellular product attributes that are reliably predictive for tumorigenicity; and (iii) the dif culty of translating preclinical test results to the clinical scenario. T e variability and biological complexity of cell-based RM products have made it dif cult to develop and adopt a standardized, prescribed set of preclinical studies that are uniformly appropriate. To illustrate this point, consider the following hypothetical example of two dif erent cell-based RM products: (i) a three-dimensional, bioresorbable polymer scaf old seeded with adipose-derived, ex vivo culture-expanded mesenchymal stem cells (MSCs) that are to be surgically implanted for nerve regeneration and (ii) a suspension of ES cell-derived cardiomyocytes that are to be directly injected into the myocardium. T ese hypothetical cell-based RM products are dif erent with respect to their tissue source, cellular phenotype, manufacturing processes, anatomical site of administration, and (most likely) in vivo tissue distribution. It follows that the preclinical programs to evaluate the safety of these two hypothetical products will differ by necessity.
For the MSC-based product, there is a risk that donor cells may become genetically unstable af er extensive manufacturing or interactions with the scaf old pre-or postimplantation. T us, testing that does not include evaluation of the intended clinical product-MSCs cultured to the end of product limit and seeded on the polymer scaf old-may not adequately inform clinical risk. T is is equally true for the second hypothetical product, but there is also a greater risk that a suspension of ES cellderived cardiomyocytes contains residual undif erentiated cells that could form teratomas af er administration. To help ensure that the tumorigenicity testing of such a product is interpretable, the study design should include groups of animals that receive undif erentiated ES cells, serial dilutions of a population of undif erentiated ES cells combined with ES cell-derived cardiomyocytes, and the f nal intended clinical product. T is approach to preclinical tumorigenicity testing, in which the panel of tests is tailored for each specif c product, is in contrast to the established rodent bioassays used for carcinogenicity testing of small-molecule pharmaceuticals.
As a result of the challenges associated with testing methods for RM products, a panel of tests that consists of both in vitro Table 1 . Assessing tumorigenic potential. Although there currently is no check-the-box standard preclinical animal study design to evaluate a cell-based RM product's ability to form tumors in vivo, an appreciation of the limitations and challenges associated with animal testing can aid in the design of product-specifi c science-based preclinical testing strategies.
Considerations for cell-based RM products Associated challenges for preclinical animal studies
The cellular component may form tumors after in vivo administration.
Comprehensive preclinical testing may be necessary to identify and minimize the risk of tumor formation.
The identical clinical product should be tested. Achieving durable cell engraftment in animals may be diffi cult.
If the cells are expected to persist in humans, durable engraftment of the cellular product is necessary for a preclinical study to be informative.
An immune response to human donor cells may prevent durable engraftment in an animal model (xenorejection). To address this caveat:
• Use of immuno-compromised (IC) rodents or immuno-suppression (IS) regimens may facilitate engraftment, but IC animals may have shorter life spans, and IS regimens may cause toxicity in the host animal or to the administered cells.
• The use of analogous animal cells may facilitate engraftment, but these cells may also have diff erent bioactivity.
Tumor formation is often a slowly occurring and rare event.
Preclinical testing that is not conducted over a suffi cient portion of the expected life span of an animal may yield a false-negative result. A large number of animals may be needed to detect rare tumor formation events.
Some animals spontaneously develop tumors that are unrelated to administration of the product.
Identifi cation of tumor origin (donor-or host-cell) is necessary. A large number of animals may be needed to distinguish spontaneous tumor formation from those due to the product.
The microenvironment may infl uence a product's tumorigenic potential. Cell delivery to an anatomical location other than the intended clinical location may not adequately inform clinical risk.
Scaff olding or other product components may provide environmental cues that infl uence bioactivity.Xenogeneic environments may not provide clinically relevant cues, which may infl uence interpretability of results.
Tumor formation may be dose dependent. It may not be possible to administer the absolute clinical dose in an animal model.
The sensitivity of testing methods may need to be confi rmed with appropriate positive controls.
A product may induce tumor formation from existing subclinical host malignant cells.
Established animal models relevant to the target patient population may not exist. 
FOCUS
and in vivo studies is of en the most informative. For example, in vitro testing may identify phenotypic and genomic markers specif c to a population of cells; however, the utility of these markers may be limited by an incomplete understanding of biomarkers that are, in fact, predictive of tumor formation. Moreover, many in vitro assays fail to account for the tumor-promoting or tumorsuppressing ef ects of the local niche within which the cells will reside af er patient administration, such as inf ammatory status, growth factor concentrations, and extracellular matrix presentation. Nevertheless, in vitro tests have utility in many instances. For example, comprehensive evaluation of a cell-based RM product's growth kinetics, including determination of proliferation rate or number of population doublings before senescence, may help inform the risk of tumor formation. It follows that although in vitro characterization and testing of a cellbased RM product is informative, complementary in vivo testing is of en, though not always, necessary.
IS MY PRODUCT CAPABLE OF TUMOR FORMATION?
T e risk of tumor formation for each cellbased RM product is dependent on a constellation of product-specif c properties.
T ese may include cell type (for example, fetal neural cells versus neonatal f broblasts), cell persistence, phenotypic plasticity, proliferative capacity, and propensity to migrate from the site of administration.
Other critical factors, such as degree of manipulation during manufacturing, the local microenvironment within which the delivered cells will eventually reside, cell dose, and immune status, may also either increase or decrease the likelihood of tumor formation. Accordingly, there is a spectrum of risk among cell-based RM products, and an understanding of these product-specif c risk factors can aid in the development of appropriate preclinical testing strategies. For instance, there is presumably less risk of tumor formation af er administration of low-passage number, dif erentiated f broblasts compared with either of the hypothetical cell-based RM products discussed above. For the former, animal studies to evaluate tumorigenicity may not be necessary; rather, in vitro characterization of the cellular product and assessment of its biological stability may be suf cient. A well-designed preclinical testing program incorporates a tiered approach that is risk based (as determined by comprehensive product characterization) and takes into account the limitations of both in vitro testing and available animal models. If evaluation of tumorigenic potential in an animal model is warranted, an appreciation of some of the associated challenges will aid in the design of an appropriate study (Table 1 ). For example, administration of human cells to an immunocompetent rodent will result in their rapid elimination. If these cells are expected to persist in the clinical setting, it would be dif cult to gauge the level of risk of tumor formation from these results alone. Similarly, an animal study that evaluates a route of product administration that is dif erent from what is proposed clinically may not adequately account for the inf uence of the local host microenvironment, which could af ect the product's ability to form tumors. For instance, results generated from the subcutaneous implantation of a cell-based RM product may not accurately ref ect the bioactivity of a product that is intended for intracranial implantation in humans. Consideration of these issues and other challenges, as highlighted above and in Table  1 , may aid in the design of an appropriate preclinical program.
FDA/CBER evaluates the safety of investigational cell-based RM products prior to administration in clinical trials. A datadriven, case-by-case approach is employed during the review process to ensure that an appropriate balance is struck between the potential risks and benef ts of a cell-based RM product. While the risk for tumor formation may exist, product characterization and preclinical testing paradigms that are appropriately designed and implemented can help to identify, minimize, and manage this risk. Bearing this in mind, there are considerations that may aid innovators during implementation of preclinical testing and product development programs: (i) T ere is a continuum of risk that is dependent on a collection of product attributes;
(ii) a preclinical testing program may need to be tailored to the specif c cellular product and level of risk; and (iii) new therapies may require new testing paradigms. Preclinical testing strategies that take into account these issues and those highlighted in Table 1 may help to strike a balance between tissue regeneration and tumor formation.
